Skip to content

Study · Animal study (in vivo) · mouse · 2014

5 results

Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis.

Lee J, Hong SW, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY

Metabolism: clinical and experimental6 May 2014Cited by 47 (Europe PMC)

PMID24933399 (opens in a new tab)DOI10.1016/j.metabol.2014.04.011 (opens in a new tab)PepBankPUB-24933399
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In high-fat-diet obese mice, exendin‑4 increased FGF21 expression.

    In plain wordsIn mice with diet-induced obesity, exendin‑4 increased FGF21 expression.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseFGF21 expression
    Study

    mousen: not reported in source

    High-fat-diet obese C57BL/6J mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1 nmol/kg/day · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Exendin-4 increased the expression of FGF21 and its receptors in high fat diet-induced obese mice.
    1 context sentence
    Summary · context
    The C57BL/6J mice were fed a low fat diet, high fat diet, or high fat diet with 1 nmol/kg/day exendin-4 intraperitoneal injection for 10 weeks.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In high-fat-diet obese mice, exendin‑4 increased FGF21 receptor expression.

    In plain wordsIn mice with diet-induced obesity, exendin‑4 increased expression of FGF21 receptors.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseFGF21 receptor expression
    Study

    mousen: not reported in source

    High-fat-diet obese C57BL/6J mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1 nmol/kg/day · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Exendin-4 increased the expression of FGF21 and its receptors in high fat diet-induced obese mice.
    1 context sentence
    Summary · context
    The C57BL/6J mice were fed a low fat diet, high fat diet, or high fat diet with 1 nmol/kg/day exendin-4 intraperitoneal injection for 10 weeks.

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 03LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In exendin‑4-treated HepG2 cells, SIRT1 inhibition reduced FGF21 mRNA expression.

    In plain wordsIn cells treated with exendin‑4, blocking SIRT1 reduced FGF21 gene expression.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFGF21 mRNA after SIRT1 inhibition
    Study

    n: not reported in source

    HepG2 cells treated with exendin-4
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    In cells treated with exendin-4, inhibition of SIRT1, but not SIRT6, by siRNA significantly repressed the expression of FGF21 mRNA, whereas decreased SIRT1 expression by inhibition of FGF21 was not observed.
    1 context sentence
    Summary · context
    HepG2 used in vitro study was treated with palmitic aicd (0.4 mM) with or without exendin-4 (100 nM) and FGF21 (50 nM) for 24 hours.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 04LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In exendin‑4-treated HepG2 cells, SIRT6 inhibition did not repress FGF21 mRNA expression.

    In plain wordsIn cells treated with exendin‑4, blocking SIRT6 did not reduce FGF21 gene expression.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeFGF21 mRNA after SIRT6 inhibition
    Study

    n: not reported in source

    HepG2 cells treated with exendin-4
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    In cells treated with exendin-4, inhibition of SIRT1, but not SIRT6, by siRNA significantly repressed the expression of FGF21 mRNA, whereas decreased SIRT1 expression by inhibition of FGF21 was not observed.
    1 context sentence
    Summary · context
    HepG2 used in vitro study was treated with palmitic aicd (0.4 mM) with or without exendin-4 (100 nM) and FGF21 (50 nM) for 24 hours.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 05LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism

    In exendin‑4-treated HepG2 cells, FGF21 inhibition did not decrease SIRT1 expression.

    In plain wordsIn cells treated with exendin‑4, blocking FGF21 did not reduce SIRT1 expression.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeSIRT1 expression after FGF21 inhibition
    Study

    n: not reported in source

    HepG2 cells treated with exendin-4
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    In cells treated with exendin-4, inhibition of SIRT1, but not SIRT6, by siRNA significantly repressed the expression of FGF21 mRNA, whereas decreased SIRT1 expression by inhibition of FGF21 was not observed.
    1 context sentence
    Summary · context
    HepG2 used in vitro study was treated with palmitic aicd (0.4 mM) with or without exendin-4 (100 nM) and FGF21 (50 nM) for 24 hours.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.